Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis

Table 1

Characteristics of included studies.

Study	Year	Country	Control	Number	Test methods	Sensitivity	Specificity	Cutoff (AFP/AFP-L3%/DCP)
Best et al. [25]	2016	Germany	CLD	367	μTAS assay	0.92	0.84	10 ng/ml, 10%, 7.5 ng/ml
Volk et al. [32]	2007	The US	Cirrhosis	253	IAUEC, EIA	0.88	0.91	23 ng/ml, 3%, 150 mAU/ml
Choi et al. [33]	2018	Korea	Cirrhosis	210	CMIA, μTAS assay, ECLIA	0.83	0.75	5 ng/ml, 4%, 20 mAU/ml
Caviglia et al. [27]	2016	Italy	CLD	98	μTAS assay	0.94	0.86	5.3 ng/ml, 1%, 0.4 ng/ml
Lim et al. [26]	2015	Korea	Cirrhosis	637	μTAS assay, EIA	0.87	0.60	20 ng/ml, 5%, 40 mAU/ml
Park et al. [34]	2017	Korea	Cirrhosis	156	μTAS assay	0.44	0.99	10 ng/ml, 7%, 40 mAU/ml
Berhane et al. [31]	2016	Japan	CLD	4476	μTAS assay	0.79	0.88	20 ng/ml, 7%, 0.48 ng/ml
Berhane et al. [31]	2016	The UK	CLD	833	μTAS assay	0.99	0.50	20 ng/ml, 7%, 0.48 ng/ml
Berhane et al. [31]	2016	Germany	CLD	1278	μTAS assay	0.95	0.54	20 ng/ml, 7%, 0.48 ng/ml
Sterling et al. [35]	2009	North America	Cirrhosis	372	LiBASys	0.77	0.59	20 ng/ml, 10%, 7.5 ng/ml
Shimizu et al. [36]	2002	Japan	Cirrhosis	90	ECLIA	0.82	0.82	20 ng/ml, 10%, 40 mAU/ml
Qin et al. [37]	2016	China	Cirrhosis	463	μTAS assay	0.89	0.75	20 ng/ml, 5%, 40 mAU/ml
Zhang et al. [38]	2019	China	CLD	364	LiBASys	0.89	0.82	7 ng/ml, 10%, 40 mAU/ml